KR20250005230A - 신경염증성 병태를 치료하는 방법 - Google Patents

신경염증성 병태를 치료하는 방법 Download PDF

Info

Publication number
KR20250005230A
KR20250005230A KR1020247037070A KR20247037070A KR20250005230A KR 20250005230 A KR20250005230 A KR 20250005230A KR 1020247037070 A KR1020247037070 A KR 1020247037070A KR 20247037070 A KR20247037070 A KR 20247037070A KR 20250005230 A KR20250005230 A KR 20250005230A
Authority
KR
South Korea
Prior art keywords
compound
alkyl
mmol
pharmaceutically acceptable
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247037070A
Other languages
English (en)
Korean (ko)
Inventor
케빈 처치
로버트 테일러
쥬얼 존스톤
한스 제이. 뫼비우스
더글라스 보트만
린 에이치. 카와스
Original Assignee
아티라 파마, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아티라 파마, 인코포레이티드 filed Critical 아티라 파마, 인코포레이티드
Publication of KR20250005230A publication Critical patent/KR20250005230A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247037070A 2022-05-04 2023-05-03 신경염증성 병태를 치료하는 방법 Pending KR20250005230A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202263338328P 2022-05-04 2022-05-04
US63/338,328 2022-05-04
US202263414111P 2022-10-07 2022-10-07
US63/414,111 2022-10-07
US202263424352P 2022-11-10 2022-11-10
US63/424,352 2022-11-10
US202363447432P 2023-02-22 2023-02-22
US63/447,432 2023-02-22
PCT/US2023/020832 WO2023215377A1 (en) 2022-05-04 2023-05-03 Methods of treating neuroinflammatory conditions

Publications (1)

Publication Number Publication Date
KR20250005230A true KR20250005230A (ko) 2025-01-09

Family

ID=86693083

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247037070A Pending KR20250005230A (ko) 2022-05-04 2023-05-03 신경염증성 병태를 치료하는 방법

Country Status (10)

Country Link
US (1) US20250275976A1 (cg-RX-API-DMAC7.html)
EP (1) EP4518865A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025515045A (cg-RX-API-DMAC7.html)
KR (1) KR20250005230A (cg-RX-API-DMAC7.html)
CN (1) CN119156217A (cg-RX-API-DMAC7.html)
AU (1) AU2023263997A1 (cg-RX-API-DMAC7.html)
CA (1) CA3248640A1 (cg-RX-API-DMAC7.html)
IL (1) IL316281A (cg-RX-API-DMAC7.html)
TW (1) TW202406554A (cg-RX-API-DMAC7.html)
WO (1) WO2023215377A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025538382A (ja) * 2022-11-18 2025-11-28 アティラ・ファーマ・インコーポレイテッド 炎症病態を治療する方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
WO2004035587A1 (en) * 2002-10-17 2004-04-29 Myriad Genetics, Inc. Reverse-turn mimetics and composition and methods relating thereto
US20140094413A1 (en) 2012-04-02 2014-04-03 Washington State University Hepatocyte growth factor (hgf) mimics as therapeutic agents
SI3464336T1 (sl) 2016-06-01 2022-06-30 Athira Pharma, Inc. Spojine
AU2021371026A1 (en) * 2020-11-02 2023-06-15 LeonaBio, Inc. Bicyclic compounds and uses thereof for the treatment of diseases
IL313039A (en) * 2021-12-17 2024-07-01 Athira Pharma Inc Uses of bicyclic compounds for the treatment of diseases

Also Published As

Publication number Publication date
CA3248640A1 (en) 2023-11-09
AU2023263997A1 (en) 2024-10-24
IL316281A (en) 2024-12-01
US20250275976A1 (en) 2025-09-04
CN119156217A (zh) 2024-12-17
WO2023215377A1 (en) 2023-11-09
TW202406554A (zh) 2024-02-16
EP4518865A1 (en) 2025-03-12
JP2025515045A (ja) 2025-05-13

Similar Documents

Publication Publication Date Title
CN107001378A (zh) 吡咯并嘧啶化合物
TWI918751B (zh) 用於治療疾病之雙環化合物及其用途
CN108602804A (zh) 烷基二氢喹啉磺酰胺化合物
EP4518865A1 (en) Methods of treating neuroinflammatory conditions
KR20240121239A (ko) 질환 치료를 위한 이환식 화합물의 용도
EP4518866A1 (en) Methods of treating fibrosis
US20250161308A1 (en) Methods of Treating Covid-Related Disorders
JP7186874B2 (ja) ピラゾリル化合物およびその使用方法
KR20250005323A (ko) 신경병증을 치료하는 방법
EA050745B1 (ru) Применение бициклических соединений для лечения заболеваний
EA049703B1 (ru) Бициклические соединения и их применение для лечения заболеваний
CN118382441A (zh) 双环化合物用于治疗疾病的用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)

R13 Change to the name of applicant or owner recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R13-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000